The global urinalysis market is expected to grow at a compound annual growth rate of 5.82% over the forecast period to reach a market size of US$3.996 billion in 2027 from US$2.689 billion in 2020.
Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, had discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.
The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24, and half by the age of 32. According to the International Diabetes Federation, about 463 million individuals, between the age of 20-79 years, had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.
However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.
Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to chronic kidney disease. According to the National Kidney Foundation, each year more people die due to CKD than breast cancer and prostate cancer. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population. Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.
Rising geriatric population and age-related diseases.
The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. A number of end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies who sell branded analyzers, thus limiting the market growth.
The COVID-19 outbreak had a detrimental impact on the total revenue of many market players. Lockdowns imposed due to the pandemic prompted patients to postpone or delay their health checkups, thus reducing the number of tests conducted and reagent sales. However, as governments increasingly loosen restrictions, there is a rise in testing numbers. Furthermore, COVID-19 is more likely to target individuals with kidney disease, kidney transplant patients, and those at risk for kidney disease, according to the National Kidney Foundation.
Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, had discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.
The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24, and half by the age of 32. According to the International Diabetes Federation, about 463 million individuals, between the age of 20-79 years, had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.
However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.
Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to chronic kidney disease. According to the National Kidney Foundation, each year more people die due to CKD than breast cancer and prostate cancer. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population. Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.
Growth Factors
Rising geriatric population and age-related diseases.
The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes, kidney and liver disease is projected to rise dramatically as the geriatric population grows. According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.
Restraints
Unfavorable reimbursement conditions
The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. A number of end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies who sell branded analyzers, thus limiting the market growth.
Impact of COVID-19 on the urinalysis market
The COVID-19 outbreak had a detrimental impact on the total revenue of many market players. Lockdowns imposed due to the pandemic prompted patients to postpone or delay their health checkups, thus reducing the number of tests conducted and reagent sales. However, as governments increasingly loosen restrictions, there is a rise in testing numbers. Furthermore, COVID-19 is more likely to target individuals with kidney disease, kidney transplant patients, and those at risk for kidney disease, according to the National Kidney Foundation.
Competitive Insight:
- October 2021 - Olive Diagnostics, a home-based Urinalysis technology developer, began a funding round supported by the Maccabi Foundation for the world's first hands-free toilet optical sensor targeting early disease detection in the elderly and pregnant women
- September 2021 - At the AACC Annual Scientific Meeting & Clinical Lab Expo, Beckman Coulter unveiled DxU Iris Workcell, a revolutionary urinalysis solution that reduces sample processing time.
- June 2020 - Healthy.io, an Israeli smartphone urinalysis and wound-care startup spent $9 million in cash to acquire fellow home-diagnostics company Inui Health.
Market Segmentation:
By Product Type
- Instruments
- Automated Urine Analyzer
- Semi-automated Urine Analyzer
- Point-of-Care Urine Analyzer
- Consumables
- Reagents
- Kits
- Dipsticks
- Disposables
By Test Type
- Biochemical Urinalysis
- Pregnancy & Fertility Urinalysis
- Sediment Urinalysis
By Application
- Urinary Tract Infections
- Diabetes
- Kidney Diseases
- Liver Diseases
- Pregnancy and Fertility
- Others
By End-User
- Hospitals & Clinics
- Diagnostic Laboratories
- Research & Academic Institutions
- Home Care Settings
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Others
- Asia Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Thailand
- Indonesia
- Others
Table of Contents
1. Introduction1.1. Market Overview1.2. Covid-19 Scenaro
1.3. Market Defnition
1.4. Market Segmentation
2. Research Methodology2.1. Research Data
2.2. Assumptions
3. Executive Summary3.1. Research Highlights
4. Market Dynamics4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Urinalysis Market Analysis, by Product Type5.1. Introduction
5.2. Instruments
5.2.1. Automated Urine Analyzer
5.2.2. Semi-automated Urine Analyzer
5.2.3. Point-of-Care Urine Analyzer
5.3. Consumables
5.3.1. Reagents
5.3.2. Kits
5.3.3. Dipsticks
5.3.4. Disposables
6. Global Urinalysis Market Analysis, by Test Type6.1. Introduction
6.2. Biochemical Urinalysis
6.3. Pregnancy & Fertility Urinalysis
6.4. Sediment Urinalysis
7. Global Urinalysis Market Analysis, by Application7.1. Introduction
7.2. Urinary Tract Infections
7.3. Diabetes
7.4. Kidney Diseases
7.5. Liver Diseases
7.6. Pregnancy and Fertility
7.7. Others
8. Global Urinalysis Market Analysis, by End-User8.1. Introduction
8.2. Hospitals & Clinics
8.3. Diagnostic Laboratories
8.4. Research & Academic Institutions
8.5. Home Care Settings
9. Global Urinalysis Market Analysis, by Geography9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. UK
9.4.4. Italy
9.4.5. Spain
9.4.6. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. South Africa
9.5.4. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. India
9.6.3. Japan
9.6.4. South Korea
9.6.5. Taiwan
9.6.6. Thailand
9.6.7. Indonesia
9.6.8. Others
10. Competitive Environment and Analysis10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. Company Profiles 11.1. ARKRAY, Inc.
11.2. 77 Elektronika Kft.
11.3. Siemens Healthineers AG
11.4. F. Hoffmann-La Roche Ltd.
11.5. Beckman Coulter, Inc.
11.6. Abbott Laboratories
11.7. Sysmex Corporation
11.8. Neomedica d.o.o.
11.9. Mindray Medical International Limited
11.10. Analis sa/nv
Companies Mentioned
- ARKRAY, Inc.
- 77 Elektronika Kft.
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd.
- Beckman Coulter, Inc.
- Abbott Laboratories
- Sysmex Corporation
- Neomedica d.o.o.
- Mindray Medical International Limited
- Analis sa/nv
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | March 2022 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 2.69 billion |
| Forecasted Market Value ( USD | $ 4 billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
